Product Spotlight

What is Cabergoline?

Approved by the Food and Drug Administration for manufacturing and prescription use in humans, Cabergoline is one of the newer substances we offer in its purest form on  As with all of our products, our USA made Cabergoline is intended to be used in research laboratories for study purposes only.  Even though the substances is FDA approved, you should not ingest our Cabergoline.

There are other names that Cabergoline can go by, even in the United States market.  Dostinex is the most well known and most frequently used prescription drug that contains Cabergoline as the active ingredient.  Coming in tablet form, it is a stark difference from the pure form we offer for your research. All prescription versions are going to come in tablet form for easy oral ingestion.

What is it Used for?

Derived from a type of ergot fungus, is a potent dopamine receptor and a pituitary gland inhibitor.  When prescribed by a doctor, it is most frequently used as the first line of defense against hyperprolactinemia.  Prolactin is the hormone that’s produced by the pituitary glands in all humans and most other mammals.  Having an over abundance of the prolactin hormone in your system leads to a condition called hyperprolactinemia.  Individuals suffering from hyperprolactinemia typically produce erratic amounts of other important hormones like estrogen, testosterone, and progesterone.  Erratic and inconsistent levels of these other hormones can lead to the following problems in both men and women:

  • Discharge from nipples
  • Reduced sexual desire
  • Infertility
  • Unexpected changes in appetite
  • Hypothalamic disease
  • Kidney disease
  • Prolactinoma (cancerous tumor)
  • Hypothyroidism

Potential Side Effects

There is no shortage of side effects when it comes to Cabergoline.  Most of the side effects are not very serious at all while some could be considered life threatening if not addressed.  As is the case with most hormone altering medications, Cabergoline supplementation has been known to alter moods and increase the frequency and severity of mood changes.  Sudden weight gain and lack of energy can be expected as your hormones reach normal levels. Even hallucinations, though rare, have been reported on a number of occasions.  The other common side effects include nausea, heartburn, dizziness, and constipation. To counteract, drink fluids and avoid dosing on an empty stomach.

The more serious side effects that need to be reported to a physician include chest pains, stomach lumps and/or pain, breast lumps and/or pain, a complete lack of urination, and the usual signs of allergic reaction.  Ignoring these symptoms can lead to potentially life threatening problems.

Efficacy of Cabergoline

For 25 years, Cabergoline has been known to be effective when treating hyperprolactinemia.  As time marched on, scientists like this reputable team from the Department of Molecular and Clinical Endocrinology and Oncology of the Federico II University of Naples explored the potential for Cabergoline to be used to fight against tumors in the pituitary glands.  Through the years, results have been perfected and the medical community appears to be inches away from discovering a pituitary tumor defeating, Cabergoline-based medication now that we are combatting HGH induced problems!

1 Verhelst, J, et al. “Cabergoline in the Treatment of Hyperprolactinemia: a Study in 455 Patients.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, July 1999,

2 Rains, C P, et al. “Cabergoline. A Review of Its Pharmacological Properties and Therapeutic Potential in the Treatment of Hyperprolactinaemia and Inhibition of Lactation.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, Feb. 1995,

3 Colao, A, et al. “Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, Nov. 1997,

4 Kuhn, E, and P Chanson. “Cabergoline in Acromegaly.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, Feb. 2017,

Leave a Reply